- Home
- CYRX vs ALT Comparison
CYRX vs ALT Comparison
Compare CYRX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | ALT |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.7M | 415.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYRX | ALT |
|---|---|---|
| Price | $11.01 | $4.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $12.83 | ★ $16.00 |
| AVG Volume (30 Days) | 351.6K | ★ 6.0M |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $243,795,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.27 | N/A |
| P/E Ratio | $8.49 | ★ N/A |
| Revenue Growth | ★ 41.27 | N/A |
| 52 Week Low | $4.58 | $2.90 |
| 52 Week High | $11.44 | $7.73 |
Technical Indicators
Market Signals| Indicator | CYRX | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 65.26 | 58.55 |
| Support Level | $10.39 | $4.03 |
| Resistance Level | $11.38 | $4.40 |
| Average True Range (ATR) | 0.47 | 0.26 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 81.44 | 99.56 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.